PMID- 32435185
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240306
IS  - 1662-5102 (Print)
IS  - 1662-5102 (Electronic)
IS  - 1662-5102 (Linking)
VI  - 14
DP  - 2020
TI  - Neuroprotective Effects of Diabetes Drugs for the Treatment of Neonatal 
      Hypoxia-Ischemia Encephalopathy.
PG  - 112
LID - 10.3389/fncel.2020.00112 [doi]
LID - 112
AB  - The perinatal period represents a time of great vulnerability for the developing 
      brain. A variety of injuries can result in death or devastating injury causing 
      profound neurocognitive deficits. Hypoxic-ischemic neonatal encephalopathy (HIE) 
      remains the leading cause of brain injury in term infants during the perinatal 
      period with limited options available to aid in recovery. It can result in 
      long-term devastating consequences with neurologic complications varying from 
      mild behavioral deficits to severe seizure, intellectual disability, and/or 
      cerebral palsy in the newborn. Despite medical advances, the only viable option 
      is therapeutic hypothermia which is classified as the gold standard but is not 
      used, or may not be as effective in preterm cases, infection-associated cases or 
      low resource settings. Therefore, alternatives or adjunct therapies are urgently 
      needed. Ongoing research continues to advance our understanding of the mechanisms 
      contributing to perinatal brain injury and identify new targets and treatments. 
      Drugs used for the treatment of patients with type 2 diabetes mellitus (T2DM) 
      have demonstrated neuroprotective properties and therapeutic efficacy from 
      neurological sequelae following HIE insults in preclinical models, both alone, or 
      in combination with induced hypothermia. In this short review, we have focused on 
      recent findings on the use of diabetes drugs that provide a neuroprotective 
      effect using in vitro and in vivo models of HIE that could be considered for 
      clinical translation as a promising treatment.
CI  - Copyright (c) 2020 Poupon-Bejuit, Rocha-Ferreira, Thornton, Hagberg and Rahim.
FAU - Poupon-Bejuit, Laura
AU  - Poupon-Bejuit L
AD  - UCL School of Pharmacy, University College London, London, United Kingdom.
FAU - Rocha-Ferreira, Eridan
AU  - Rocha-Ferreira E
AD  - Centre for Perinatal Medicine and Health, Institute of Clinical Sciences, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Thornton, Claire
AU  - Thornton C
AD  - Department of Comparative Biomedical Sciences, Royal Veterinary College, London, 
      United Kingdom.
FAU - Hagberg, Henrik
AU  - Hagberg H
AD  - Centre for Perinatal Medicine and Health, Institute of Clinical Sciences, 
      Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
FAU - Rahim, Ahad A
AU  - Rahim AA
AD  - UCL School of Pharmacy, University College London, London, United Kingdom.
LA  - eng
GR  - MR/R015325/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/S036784/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/R025134/1/MRC_/Medical Research Council/United Kingdom
GR  - MR/N026101/1/MRC_/Medical Research Council/United Kingdom
GR  - WT_/Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Review
DEP - 20200506
PL  - Switzerland
TA  - Front Cell Neurosci
JT  - Frontiers in cellular neuroscience
JID - 101477935
PMC - PMC7218053
OTO - NOTNLM
OT  - cerebral palsy
OT  - diabetes
OT  - hypothermia
OT  - hypoxic-ischemic encephalopathy
OT  - neuroprotection
OT  - perinatal brain injury
EDAT- 2020/05/22 06:00
MHDA- 2020/05/22 06:01
PMCR- 2020/01/01
CRDT- 2020/05/22 06:00
PHST- 2020/02/14 00:00 [received]
PHST- 2020/04/08 00:00 [accepted]
PHST- 2020/05/22 06:00 [entrez]
PHST- 2020/05/22 06:00 [pubmed]
PHST- 2020/05/22 06:01 [medline]
PHST- 2020/01/01 00:00 [pmc-release]
AID - 10.3389/fncel.2020.00112 [doi]
PST - epublish
SO  - Front Cell Neurosci. 2020 May 6;14:112. doi: 10.3389/fncel.2020.00112. 
      eCollection 2020.